Teligent Surprised By Orphan Generic Setback
FDA Wants More Information On Complex Generic
US niche generics specialist Teligent has expressed surprise at a complete response letter issued by the FDA over an application for a generic of an orphan drug.
You may also be interested in...
Rather than blame employees for ignoring 397 product complaints, Teligent should have fixed complaint handling system, US FDA warning letter says.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.